YZYue Zhang

Yue Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yue Zhang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the cost-effectiveness of next-generation sequencing strategies for familial hypercholesterolemia cascade screening in Thailand

    by Yue Zhang, Parnnaphat Luksameesate, Vorasuk Shotelersuk, Jing Lou, Sutinee Soopairin, Chanthawat Patikorn, Nattanichcha Kulthanachairojana, Pawarut Wongmanovisut, Thanapol Khuharatanachai, Hwee-Lin Wee, et al.

    Background: Genetic cascade screening of familial hypercholesterolemia (FH) effectively prevents cardiovascular complications, but it remains unclear how health systems should roll out genetic testing over time. We developed a policy-relevant, forward-looking framework for stepwise economic evaluation on genetic testing, using FH cascade testing in Thailand as a case study. Methods: We constructed a decision tree-Markov hybrid model for a cohort of 35-year-old probands with low-density lipoprotein cholesterol above 4.9 mmol/L and their first- and second-degree relatives. We performed stepwise evaluations on conventional three-gene panel testing, whole-exome sequencing (WES), and onward to emerging long-read sequencing (LRS), compared with standard of care from a societal perspective. Conventional economic evaluation compared panel testing and WES using currently available evidence, while early economic evaluation was applied to LRS to identify target product profiles and explore uncertainties. Results: The analyses show that panel- and WES-based cascade screening are cost-effective versus standard of care, with incremental cost-effectiveness ratios (ICERs) of Thai baht (THB) 81,494 (€2,146/$2,371) and THB 74,641 (€1,966/$2,172) per quality-adjusted life-year (QALY), respectively. Compared with panel testing, WES generates 0.055 incremental QALYs at an ICER of THB 50,703 (€1,335/$1,475)/QALY. LRS is also cost-effective versus standard of care under target costs and yields 0.04 incremental QALYs/person versus WES, but requires cost reductions of 16.33% to THB 33,468/proband and 46.05% to THB 21,580/proband to surpass WES and dominate the market, respectively. Conclusions: This forward-looking, stepwise evaluation demonstrates that next-generation sequencing for FH cascade testing can be economically viable in Thailand while advancing precision health under universal healthcare.

  • Open Access

    Refining a precision medicine economic evaluation framework: Insights from a multi-stakeholder consultative workshop

    by Dimple Butani, Yah Ru Juang, Laura Huey Mien Lim, Alec Morton, Jingmei Li, Jamaica Briones, Jing Lou, Naline Gandhi, Hwee-Lin Wee, Joanne Yuen Yie Ngeow, et al.

  • Open Access

    Financing and health system capacity for precision medicine in Asia: a six country landscape analysis

    by Adena Li Tyin Peh, Yot Teerawattananon, Jeanette Xue Yan Yuen, Nordin Charafi, Dicky Levenus Tahapary, Jiahua Leng, Alec Morton, Sheyu Li, Woo Jin Kim, Bin Alwi Zilfalil, et al.

    Background: Precision medicine (PM) adoption is accelerating across Asia, but implementation remains uneven due to differences in financing, infrastructure, governance, and health-system readiness. Objectives: To examine how six Asian countries (Singapore, South Korea, China, Malaysia, Thailand, and Indonesia) adopt, finance, and integrate PM technologies, and identify common implementation patterns and challenges. Methods: A landscape review of peer-reviewed literature, government publications, and HTA reports (2010-2026) was conducted, supplemented by stakeholder consultations. PM applications were grouped into public health screening (hereditary breast and ovarian cancer [HBOC] and familial hypercholesterolemia [FH] cascade testing), next-generation sequencing (NGS) applications (rare diseases, oncology, pharmacogenomics), and AI-enabled PM. Evidence was synthesized across access, awareness, reimbursement, and implementation. Results: Public health genomic screening demonstrated the highest implementation readiness, followed by precision oncology, while rare disease diagnostics remained infrastructure-dependent and pharmacogenomics and AI-enabled PM platforms were at earlier stages. Four readiness profiles emerged: highly aligned systems; reimbursement-constrained systems with strong governance and infrastructure; systems strengthening governance, public financing and infrastructure; and strategy-led systems expanding implementation through pilot programs and referral centers. Conclusions: PM implementation across Asia remains heterogeneous. The identified readiness profiles highlight governance, financing, and infrastructure priorities for sustainable and equitable PM diffusion.


  • Open Access

    An Updated Systematic Review on Asthma Exacerbation Risk Prediction Models Between 2017 and 2023: Risk of Bias and Applicability

    by Anqi Liu, Yue Zhang, Chandra Yadav, Wenjia Chen

    Background: Accurate risk prediction of exacerbations in asthma patients promotes personalized asthma management. Objective: This systematic review aimed to provide an update and critically appraise the quality and usability of asthma exacerbation prediction models which were developed since 2017. Methods: In the Embase and PubMed databases, we performed a systematic search for studies published in English between May 2017 and August 2023, and identified peer-reviewed publications regarding the development of prognostic prediction models for the risk of asthma exacerbations in adult patients with asthma. We then applied the Prediction Risk of Bias Assessment tool (PROBAST) to assess the risk of bias and applicability of the included models. Results: Of 415 studies screened, 10 met eligibility criteria, comprising 41 prediction models. Among them, 7 (70%) studies used real-world data (RWD) and 3 (30%) were based on trial data to derive the models, 7 (70%) studies applied machine learning algorithms, and 2 (20%) studies included biomarkers like blood eosinophil count and fractional exhaled nitric oxide in the model. PROBAST indicated a generally high risk of bias (80%) in these models, which mainly originated from the sample selection (“Participant” domain, 6 studies) and statistical analysis (“Analysis” domain, 7 studies). Meanwhile, 5 (50%) studies were rated as having a high concern in applicability due to model complexity. Conclusion: Despite the use of big health data and advanced ML, asthma risk prediction models from 2017– 2023 had high risk of bias and limited practical use. Future efforts should enhance generalizability and practicality for real-world implementation.